U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H26N2O2
Molecular Weight 362.4656
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOLIFENACIN

SMILES

c1ccc(cc1)[C@@]2([H])c3ccccc3CCN2C(=O)O[C@@]4([H])CN5CCC4CC5

InChI

InChIKey=FBOUYBDGKBSUES-VXKWHMMOSA-N
InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: http://www.rxlist.com/vesicare-drug.htm https://www.drugs.com/mtm/solifenacin.html http://www.wikidoc.org/index.php/Solifenacin

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in rat. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.0 nM [Ki]
125.0 nM [Ki]
25.0 nM [Ki]
7.73 null [pKi]
7.46 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VESICARE

Approved Use

VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency (1)

Launch Date

1.10082235E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
14.1 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
820 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
50.8 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
SOLIFENACIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg single, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources: Page: p.1028
healthy, 19-40
n = 6
Health Status: healthy
Age Group: 19-40
Sex: M
Population Size: 6
Sources: Page: p.1028
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.1029
healthy, 20-35
n = 8
Health Status: healthy
Age Group: 20-35
Sex: M
Population Size: 8
Sources: Page: p.1029
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.4
unhealthy
n = 1233
Health Status: unhealthy
Condition: Overactive bladder
Population Size: 1233
Sources: Page: p.4
Disc. AE: Dry mouth...
AEs leading to
discontinuation/dose reduction:
Dry mouth (1.5%)
Sources: Page: p.4
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Disc. AE: Angioedema, Anaphylactic reaction...
AEs leading to
discontinuation/dose reduction:
Angioedema
Anaphylactic reaction (rare)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Dry mouth 1.5%
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.4
unhealthy
n = 1233
Health Status: unhealthy
Condition: Overactive bladder
Population Size: 1233
Sources: Page: p.4
Angioedema Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Anaphylactic reaction rare
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Drug forecast--solifenacin: an investigational anticholinergic for overactive bladder.
2004 May
Solifenacin in overactive bladder: a viewpoint by Hashim Hashim.
2005
Solifenacin in overactive bladder syndrome: a viewpoint by Scott Serels.
2005
Solifenacin in overactive bladder syndrome.
2005
Overactive bladder in the elderly: a guide to pharmacological management.
2005
[Drug discovery in the fields of urology: tamsulosin and solifenacin].
2005 Nov
The Q-T interval and antimuscarinic drugs.
2005 Nov
Solifenacin versus tolterodine--a head-to-head study: finally! But not final?
2005 Nov
Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.
2005 Oct 20
Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.
2005 Sep
Solifenacin in overactive bladder syndrome.
2006
Gateways to clinical trials.
2006 Apr
The causes and consequences of overactive bladder.
2006 Apr
Solifenacin significantly improves all symptoms of overactive bladder syndrome.
2006 Aug
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
2006 Aug
New developments in the treatment of urinary incontinence.
2006 Dec
Solifenacin succinate (VESIcare): overactive bladder therapy.
2006 Dec
[Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder].
2006 Dec
Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
2006 Dec
Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.
2006 Dec
Muscarinic receptors in the bladder: from basic research to therapeutics.
2006 Feb
New drugs 06, part I.
2006 Feb
Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
2006 Jan
Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
2006 Jan
Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.
2006 Jul
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
2006 Jul
[Oral anticholinergics in overactive bladder].
2006 Jul
Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
2006 Jun
Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.
2006 Jun
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
2006 Mar
The emergence of new drugs for overactive bladder.
2006 Mar
Management of overactive bladder and urge urinary incontinence in the elderly patient.
2006 Mar
Pharmacologic management of overactive bladder: practical options for the primary care physician.
2006 Mar
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
2006 Mar
Gateways to clinical trials.
2006 May
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
2006 Nov
Gateways to clinical trials.
2006 Nov
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
2006 Nov
Solifenacin.
2006 Nov
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.
2006 Oct 18
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.
2006 Sep
Solifenacin succinate for the treatment of symptoms of overactive bladder.
2006 Sep
Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test.
2007 Feb 28
Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency.
2007 Jan
Redefining response in overactive bladder syndrome.
2007 Jan
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
2007 Jan
Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
2007 Jul
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
2007 Mar
An unusual cause of postoperative detrusor overactivity.
2007 Oct
Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.
2007 Sep
Patents

Sample Use Guides

5 mg tablet taken once daily, and if well tolerated may be increased to 10 mg once daily.
Route of Administration: Oral
The inhibitory effect of solifenacin (dose range: 10^-10 - 10^-6 M) for bladder smooth muscle cells (pK(i)=8.12) was 3.6-fold more potent than that for salivary gland cells (pK(i)=7.57).
Name Type Language
SOLIFENACIN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
SOLIFENACIN [INN]
Common Name English
NSC-759144
Code English
SOLIFENACIN [MI]
Common Name English
SOLIFENACIN [WHO-DD]
Common Name English
SOLIFENACIN [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC G04CA53
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
NDF-RT N0000000125
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
WHO-ATC G04BD08
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
NDF-RT N0000000125
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
WHO-VATC QG04CA53
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
LIVERTOX 892
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
NDF-RT N0000000125
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
WHO-VATC QG04BD08
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
NCI_THESAURUS C29704
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
NDF-RT N0000175700
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
Code System Code Type Description
RXCUI
322167
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
MESH
C441209
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
LACTMED
Solifenacin
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
MERCK INDEX
M10108
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY Merck Index
INN
8155
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
DRUG CENTRAL
2457
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
DRUG BANK
DB01591
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
EVMPD
SUB21589
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
EPA CompTox
242478-37-1
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
CAS
242478-37-1
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
IUPHAR
7483
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
ChEMBL
CHEMBL1734
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
NCI_THESAURUS
C75284
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
FDA UNII
A8910SQJ1U
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
PUBCHEM
154059
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
WIKIPEDIA
SOLIFENACIN
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
RXCUI
477364
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
ALTERNATIVE